CN113952366A - Configuration method and application for preventing and treating new coronavirus - Google Patents
Configuration method and application for preventing and treating new coronavirus Download PDFInfo
- Publication number
- CN113952366A CN113952366A CN202111025789.2A CN202111025789A CN113952366A CN 113952366 A CN113952366 A CN 113952366A CN 202111025789 A CN202111025789 A CN 202111025789A CN 113952366 A CN113952366 A CN 113952366A
- Authority
- CN
- China
- Prior art keywords
- potassium
- low
- iodine
- kelp powder
- kelp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 28
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 79
- 239000011591 potassium Substances 0.000 claims abstract description 75
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 75
- 239000000843 powder Substances 0.000 claims abstract description 65
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 54
- 239000011630 iodine Substances 0.000 claims abstract description 54
- 241000282414 Homo sapiens Species 0.000 claims abstract description 26
- 239000000126 substance Substances 0.000 claims abstract description 20
- 206010020772 Hypertension Diseases 0.000 claims abstract description 19
- 241000700605 Viruses Species 0.000 claims abstract description 18
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 11
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 8
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 4
- 239000007924 injection Substances 0.000 claims abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
- 239000007921 spray Substances 0.000 claims abstract description 4
- 241000206607 Porphyra umbilicalis Species 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 39
- 235000010408 potassium alginate Nutrition 0.000 claims description 22
- 239000000737 potassium alginate Substances 0.000 claims description 22
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 22
- 239000011734 sodium Substances 0.000 claims description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 14
- 241001474374 Blennius Species 0.000 claims description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 13
- 239000003957 anion exchange resin Substances 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 239000000783 alginic acid Substances 0.000 claims description 12
- 229960001126 alginic acid Drugs 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 150000004781 alginic acids Chemical class 0.000 claims description 12
- 239000003729 cation exchange resin Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- 239000003480 eluent Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 9
- 235000010413 sodium alginate Nutrition 0.000 claims description 9
- 239000000661 sodium alginate Substances 0.000 claims description 9
- 229940005550 sodium alginate Drugs 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 7
- 235000011164 potassium chloride Nutrition 0.000 claims description 7
- 235000010410 calcium alginate Nutrition 0.000 claims description 6
- 239000000648 calcium alginate Substances 0.000 claims description 6
- 229960002681 calcium alginate Drugs 0.000 claims description 6
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 4
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 210000002421 cell wall Anatomy 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000012510 hollow fiber Substances 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 150000004804 polysaccharides Chemical class 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 23
- 206010035664 Pneumonia Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 210000001331 nose Anatomy 0.000 abstract description 2
- 210000004204 blood vessel Anatomy 0.000 description 30
- 230000036772 blood pressure Effects 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 17
- 235000015424 sodium Nutrition 0.000 description 17
- 229910052708 sodium Inorganic materials 0.000 description 17
- 239000003814 drug Substances 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 10
- 230000023555 blood coagulation Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000007599 discharging Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000001736 capillary Anatomy 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 229910001415 sodium ion Inorganic materials 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 208000007117 Oral Ulcer Diseases 0.000 description 4
- 208000002399 aphthous stomatitis Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000007565 gingivitis Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- -1 iodophors Chemical class 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960002003 hydrochlorothiazide Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 3
- 239000001230 potassium iodate Substances 0.000 description 3
- 235000006666 potassium iodate Nutrition 0.000 description 3
- 229940093930 potassium iodate Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010002482 Angiosclerosis Diseases 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000009019 Pericoronitis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241001678561 Sarbecovirus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- YADZBEISHVCBSJ-UHFFFAOYSA-N [I].OCC(O)CO Chemical compound [I].OCC(O)CO YADZBEISHVCBSJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019884 chronic gingivitis Diseases 0.000 description 2
- 208000001277 chronic periodontitis Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
- 150000002497 iodine compounds Chemical class 0.000 description 2
- 229940035535 iodophors Drugs 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229940070017 potassium supplement Drugs 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 229940086245 acetaminophen 650 mg Drugs 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B7/00—Halogens; Halogen acids
- C01B7/13—Iodine; Hydrogen iodide
- C01B7/14—Iodine
- C01B7/16—Preparation from seaweed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Medical Informatics (AREA)
Abstract
The invention relates to a configuration method and application for preventing and treating new coronavirus, wherein the method comprises the following steps: firstly preparing low-potassium kelp powder, preparing the low-potassium kelp powder into spray containing the low-potassium kelp powder by using a nanotechnology for use in a nasal cavity and a throat, preparing the low-potassium kelp powder into normal saline for human body injection, and preparing the low-potassium kelp powder into capsules or tablets, wherein the reason for human death caused by neocoronary pneumonia is as follows: the other method is to extract iodine simple substance from cydiodine tablet or extract iodine simple substance from sea tangle laver, and prepare an atomizer together with the low potassium sea tangle powder, and the atomizer has double effects of preventing and treating new coronavirus and variant virus through nose, mouth and throat, and can also be used for preventing and treating hypertension, critical hypertension, myocardial infarction and cerebral infarction.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to a configuration method and application for preventing and treating new coronavirus.
Background
The novel coronavirus (Corona Virus Disease 2019) is an infectious Disease caused by the infection of a human body by the novel coronavirus (SARS-Cov-2), the symptoms of the coronavirus mainly comprise symptoms such as fever, cough, breathlessness, dyspnea and the like, and pneumonia, acute respiratory distress syndrome, renal failure and the like can be caused, and even death can be caused. Coronaviruses belong to the family coronaviridae in phylogenetic classification. The coronavirus is a positive strand single strand RNA virus with an outer mantle (envelope), the diameter of the coronavirus is about 80-120 nm, the genetic material of the coronavirus is the largest of all RNA viruses, and the coronavirus can only infect human, mouse, pig, cat, dog and poultry vertebrates generally.
The novel coronavirus enters a human body from a respiratory tract, the respiratory tract consists of a nasal cavity, a throat, a trachea, a bronchiole, a respiratory bronchiole, a alveolar duct and alveoli, and when the novel coronavirus breathes in, gas enters the alveoli from the nasal cavity to exchange gas and then is exhaled. From the nasal cavity to the alveolus, the pathogenic agent attacks the lung, causing rhinitis (common cold), pharyngolaryngitis, tracheobronchitis and pneumonia.
For respiratory virus infection, there is a lack of effective therapeutic drugs worldwide. In the new coronary pneumonia which is outbreaked in a large area in the world, viruses invade nasal mucosa and multiply in alveoli, so that the mankind is inexperienced and the new coronary pneumonia changes from mild pneumonia to severe pneumonia and is critical to death. Although respiratory tract infection caused by bacteria, mycoplasma, chlamydia, fungi and the like can be resisted by antibiotics, the occurrence of drug-resistant bacteria is a difficult problem in modern medicine.
In view of the above, there is a need for a pharmaceutical formulation and application that can kill pathogens causing respiratory tract infection efficiently, and kill new coronaviruses more safely and rapidly.
Disclosure of Invention
The invention aims at solving the problem that the current new coronavirus variant Dermatope, C1.1.2 virus rampant, invents a configuration method for preventing and treating the new coronavirus and application thereof, wherein the method comprises the following steps: preparing low-potassium kelp powder, preparing spray containing the low-potassium kelp powder for nasal cavity and throat, preparing normal saline into normal saline for human body injection, and preparing the low-potassium kelp powder into capsules or tablets, wherein the reason for death of people caused by the neocoronary pneumonia is as follows: the other method is to extract iodine simple substance from cydiodine tablet or kelp by ion exchange resin to kill new coronavirus, and to produce an atomizer with low potassium kelp powder to kill new coronavirus and variant virus through nasal cavity, throat and throat.
The invention has two technical characteristics:
firstly, the low-potassium kelp powder is adopted, potassium is supplemented and sodium is discharged, the principle is recognized by global medical scientists, when the low-potassium kelp powder is absorbed by a human body, the low-potassium kelp powder has the functions of supplementing potassium and discharging sodium, the maximum technical bright point of the low-potassium kelp powder has the function of softening blood vessels, preventing myocardial infarction and cerebral infarction, dredging blood vessel and preventing blood coagulation lumps, and removing impurities on blood vessel walls in main arteries, arterioles and capillaries of the human body, sodium attached to the blood vessel walls is subjected to displacement reaction and changed into low-molecular sodium alginate, the low-molecular sodium alginate is discharged from the body along with the blood major circulation and the urinary system, potassium elements enter the blood vessel walls and then disperse lumps, coagulates, thrombus, blood fat and other impurities in the blood coagulation, and the purposes of supplementing potassium and discharging sodium, softening blood vessels and regulating blood pressure are achieved along with the discharge of the sodium alginate.
Finally, the blood vessel of the lung is softened and endowed with elasticity, and the blood vessel is not agglomerated and hardened, so that the pulmonary fibrosis of the young state of the blood vessel is avoided, the lung of a patient can self-breathe, a breathing machine is not needed, and the self-rescue aim is achieved.
Therefore, the effect of the low molecular state potassium alginate on hypertension, diabetes, hyperlipidemia, hyperuricemia, coronary heart disease, cerebrovascular disease and the like can not only improve symptoms, but also can completely eliminate disease roots with high possibility and high price.
The preparation method of the low-potassium kelp powder comprises the following steps:
the method comprises the following steps: after the kelp is cleaned, cellulase with the amount of 0.5 percent of the dry kelp is added to promote the enzymolysis of partial cell walls of the kelp into glucose micromolecules so as to improve the extraction rate of alginic acid.
Step two: adding Na with the mass fraction of 3 percent after the kelp is subjected to enzymolysis2CO3The solution is digested at 50 ℃ for 3 h; adding alkali solution to convert calcium alginate into soluble sodium alginate, adding hydrochloric acid, converting calcium alginate into alginic acid under the action of hydrochloric acid, adding edible potassium chloride into alginic acid at a ratio of potassium chloride to alginic acid of 0.1:300, and filtering to remove residue to obtain potassium alginate.
Step three: adding alginate lyase into potassium alginate for degradation to obtain filtrate, wherein the optimal enzymolysis reaction conditions are that the pH is 5.0, the temperature is 45 ℃, the reaction time is 18h, and the enzyme adding amount is 100U/g.
Step four: ultrafiltering the filtrate by membrane separation technology, adding anhydrous ethanol to precipitate flocculent potassium alginate, and drying to obtain micromolecular potassium alginate, i.e. low-potassium kelp powder.
Secondly, the iodine has strong sterilization and special functions of adsorption, oxidation, virus resistance, DNA interaction and the like. However, since iodine is easily sublimed, it is common to compound iodine with various substrates to improve its stability, and conventional iodine compounds such as iodophors, iodine tincture, iodine anid, and cydiodine tablets, etc. Wherein the iodine tincture: can be used for treating skin infection and disinfection. Iodine glycerin: can be used for treating oral ulcer, gingivitis, and pericoronitis. Cydiodine tablet for treating chronic pharyngolaryngitis, oral ulcer, chronic gingivitis and periodontitis.
Iodine is a strong oxidant, can halogenate proteins of pathogenic microorganisms such as viruses, bacteria, fungi and the like, destroys active groups of protoplasm proteins of the viruses, the bacteria, the fungi and the like, is combined with amino acid of the proteins to denature the proteins so as to lose activity, and has strong killing effect. Moreover, iodine has very strong penetrating power to virus, bacteria and the like, and has quick action. It is surprising that iodine is used to kill respiratory infectious viruses, including new corona viruses.
Iodine is iodine simple substance or molecule, and the iodine simple substance or molecule is dissolved in water to prepare low-concentration iodine solution.
The preparation method of the iodine simple substance comprises the following steps:
the method comprises the following steps: selecting dried seaweed plants, washing the seaweed plants, placing the washed seaweed plants in a high-pressure container, carrying out heating treatment, placing the seaweed plants in iodine-free water for leaching after the heating treatment, and keeping the iodine-free water at a constant temperature.
Step two: and (3) performing primary filtration to obtain a tawny filtrate, sequentially passing the filtrate through middle control fiber ultrafilters of different specifications to remove substances such as macromolecular protein, polysaccharide and the like, and performing vacuum concentration by using a rotary evaporator to obtain a concentrated solution.
Step three: respectively passing the concentrated solution through anion exchange resin and cation exchange resin, adjusting the pH value of the concentrated solution passing through the anion exchange resin, and collecting the effluent passing through the anion exchange resin; adjusting the pH value of the concentrated solution passing through the cation exchange resin, collecting the effluent passing through the cation exchange resin, respectively eluting the anion exchange resin and the cation exchange resin, and collecting the eluent.
Step four: and (4) iodolysis: firstly, sulfuric acid is dropped into the eluent to acidify the eluent, and then NaNO is dropped into the eluent2The solution, the eluent has brownish black precipitate.
Step five: centrifugal separation and refining: and (3) standing and clarifying the solution obtained in the fourth step, sucking out the supernatant, transferring the residual solution and the brownish black precipitate into a centrifugal test tube for centrifugal separation, sucking out the supernatant in the centrifugal test tube after centrifugal separation to obtain crude iodine, adding the crude iodine into concentrated sulfuric acid for melting, and cooling and crystallizing to obtain the pure iodine simple substance.
Further, the seaweed plant is one or more of kelp, laver and seaweed.
Further, the high-pressure container is a pressure cooker, and the pressure is one standard atmospheric pressure, namely 0.1 MPa.
Further, the heating temperature of the heating treatment was 120 ℃ and the heating time was 30 minutes.
Further, the leaching time was 12 hours.
Further, the constant temperature of the constant temperature is 49-51 ℃.
Further, the hollow fiber ultrafilter had a pass molecular weight of 80000, 30000, 10000, and 3000, respectively.
Further, the rotary evaporator was operated at 80 ℃ and vacuum concentration was carried out at a normal atmospheric pressure.
Further, the pH value of the concentrated solution passing through the anion exchange resin is 3-4, and the pH value of the concentrated solution passing through the cation exchange resin is 9-10.
Further, 6 ml of sulfuric acid was added dropwise, and the concentration of the NaNO2 solution was 10% added dropwise.
The invention has the beneficial effects that: can prevent and treat new coronavirus, is an ideal biological medical product, can be used in medical health systems, families and social public places, and benefits all mankind.
Drawings
FIG. 1 is a flow chart of the preparation method of the low-potassium kelp powder of the invention;
FIG. 2 is a flow chart of the method for preparing elemental iodine according to the present invention;
FIG. 3 is a molecular formula of the low-potassium kelp powder of the invention.
Detailed Description
So that the manner in which the objects, features and advantages of the present invention are attained and can be understood in detail, a more particular description of the invention, briefly summarized above, may be had by reference to the appended drawings. The present invention will be described below with reference to specific examples, but the present invention is not limited thereto.
The embodiment of the invention discloses a configuration method for preventing and treating new coronavirus and application thereof, aiming at the mutation delta of the current new coronavirus, C1.1.2 virus rampant, wherein the method comprises the following steps: preparing low-potassium kelp powder, preparing spray containing the low-potassium kelp powder for nasal cavity and throat, preparing normal saline into normal saline for human body injection, and preparing the low-potassium kelp powder into capsules or tablets, wherein the reason for death of people caused by the neocoronary pneumonia is as follows: the other method is to extract iodine simple substance from kelp by ion exchange resin to kill new coronavirus, and to produce an atomizer with low potassium kelp powder to kill new coronavirus and variant virus through nose, mouth and throat.
At present, a coronavirus universal vaccine is being developed, which is reported in website [ british "daily news bulletin" 8 month and 18 days ] subject: pioneering research may push out "ideal" vaccines to prevent future epidemics, and "several companies" are already in the "contract phase" of developing vaccines.
Researchers recruited 8 SARS convalescent, 10 healthy people and 10 new coronary pneumonia convalescent, and compared the immune response of the three groups of people before and after vaccination with the existing new coronary vaccine.
Researchers especially want to understand whether antibodies elicited in SARS survivors can eliminate SARS virus, new corona virus, and other Sarbecovirus (subgenus to which new corona virus belongs), including viruses that may be transmitted by animals.
Before vaccination, detectable neutralizing antibodies against SARS virus were present in SARS survivors, but no or only low levels of neutralizing antibodies against the new coronavirus.
After two doses of the pfeira mRNA vaccine, all showed high levels of neutralizing antibodies that were able to cope with the new coronaviruses as well as the SARS virus. Most importantly, only SARS survivors have extensive neutralizing antibodies present and can cope with 10 Sarbecovirus viruses that were selected for testing.
One of the authors of the research reports, the national center for infectious diseases in singapore, responsible for professor david rieger, provides a strategy for dealing with the immune evasion exhibited by emerging viral variants against first-generation vaccines.
The data source is the Singapore Ministry of health.
Singapore became the first world country to undergo autopsy for new coronavirus cadavers. Through thorough investigation, it was found that the new coronavirus, a bacterium exposed to radiation, clotted in the blood and caused human death.
Research finds that the new coronary pneumonia can cause blood clots, cause blood coagulation of a human body, cause venous blood coagulation and make breathing of the human body difficult; because the brain, heart and lungs are unable to receive oxygen, people die quickly.
To ascertain the cause of respiratory insufficiency, Singapore physicians did not follow the protocol of the world health organization and performed an autopsy on COVID-19. After the physician opens and carefully examines the arm, leg and other parts of the body, they notice the vessel expansion, filling with blood clots, obstructing blood flow, and also reducing the oxygen flow in the body, resulting in the death of the patient. The Ministry of health of Singapore immediately changed the treatment of new coronary pneumonia and administered aspirin to positive patients after learning the results of this study. I started taking 100mg and Imromac. As a result, the patient starts to recover and their health starts to improve. The singapore ministry of health has evacuated 1.4 million patients in a day and has them home.
After a period of scientific discovery, singapore's doctor explained: "this is only a treatment for intravascular coagulation", an anti-inflammatory and anti-coagulant drug (aspirin), indicating that the disease is curable.
According to other singapore scientists, ventilators and intensive care units were not needed at all at that time. Protocols for this purpose have been published in singapore.
Covid-19 is a bacterium that is exposed to radiation only. Care should be taken only in people with low immunity. This radiation also causes inflammation and hypoxia. The patient should take aspirin-100 mg and aprenix or acetaminophen 650 mg.
In view of the above description, no real cure method for the new coronavirus variation occurred in the sea and abroad is found, and the invention has two technical characteristics:
firstly, adopting low-potassium kelp powder, supplementing potassium and discharging sodium, which is a principle recognized by global medical scientists, when low-molecular-state potassium alginate is absorbed by a human body, the low-molecular-state potassium alginate has the functions of supplementing potassium and discharging sodium, the maximum technical bright point of the low-molecular-state potassium alginate has the function of softening blood vessels, preventing myocardial infarction and cerebral infarction, dredging blood coagulation lumps, and removing impurities on blood vessel walls in main arteries, arterioles and capillaries of the human body, wherein sodium attached to the blood vessel walls is subjected to replacement reaction to become low-molecular-state sodium alginate which is discharged from the body along with the blood circulation and the urinary system, and potassium element enters the blood vessel walls to disperse lumps, thrombus, blood fat and other impurities in the blood coagulation, so as to achieve the purposes of supplementing potassium and discharging sodium, softening blood vessels and regulating blood pressure along with the discharge of the sodium alginate.
Finally, the blood vessel of the lung is softened and endowed with elasticity, and the blood vessel is not agglomerated and hardened, so that the pulmonary fibrosis of the young state of the blood vessel is avoided, the lung of a patient can self-breathe, a breathing machine is not needed, and the self-rescue aim is achieved.
Vitamin K is published in the website of Wei newspaper of England 6.5.month to resist new crown pneumonia, and can prevent respiratory distress and death caused by pulmonary fibrosis! Advocated Life conservation from the K-containing food cheese broccoli, Meibo, etc. through dietary impedance pulmonary fibers! The disease-treating theory is that K element can soften blood vessels in lung! The low-potassium kelp powder contains a large amount of K element, so that the sodium salt block attached to the capillary vessel wall in the lung can be separated by a replacement reaction and becomes sodium alginate which is discharged out of the body along with the blood flow of thrombus, the blood coagulation block is prevented, the K element is dissolved in the capillary vessel to make the capillary vessel soft and elastic and become vitality in a young state, the lung can gradually breathe in a self-control manner, the generation of pulmonary fibrosis and blood coagulation can not occur, the impedance of new coronary pneumonia can seriously occur, and after the kelp powder is used by normal people, the aim of preventing diseases can be fulfilled.
Sodium is one of the vital elements, is mainly present in extracellular fluid, and can maintain water balance in vivo and muscle excitability. The daily intake of sodium is preferably 1100-3300 mg. Most of the sodium in the diet is in the form of sodium chloride, which is the main component of common salt. In addition to sodium in common salt, sodium is present in almost all foods in varying amounts.
Excessive intake of sodium salts is a significant cause of the development of hypertension. When the concentration in the blood vessel is too high, part of sodium ions can adhere to the inner wall of the blood vessel along with other substances such as cholesterol and the like and gradually permeate into the blood vessel wall, so that on one hand, the blood vessel loses elasticity and becomes stiff, the blood pressure is increased, and finally, the cerebral vessels are ruptured and bleed; on the other hand, thrombus is formed on the basis of angiosclerosis, so that heart and cerebral embolism are caused, and coronary heart disease and cerebral infarction are formed.
The world health organization advocates: the daily intake of sodium salt should be controlled within 5-6 g, but the residents in China often exceed standards. The human body absorbs potassium ions, potassium and sodium are subjected to ion exchange, and the sodium ions are discharged out of the body, so that the concentration of the sodium ions in blood vessels is reduced, the blood pressure rise and the angiosclerosis are prevented, and the occurrence of hypertension and cardiovascular and cerebrovascular diseases is avoided. Potassium can also activate cardiac muscle function, and can effectively recover and strengthen the self-regulation function of human body to blood pressure.
The low potassium kelp powder improves microcirculation, which is related to the improvement of vegetative nerve function, because it changes the regulating function of nerve to microvasculature and solves the microcirculation disturbance. Modern medicine considers that: the development of hypertension, diabetes, hyperlipidemia, hyperuricemia are closely related to microcirculation disturbance. The disease roots of the above diseases can be removed as long as the microcirculation disturbance is completely removed, and the low-potassium kelp powder has the effect.
Therefore, the low-potassium kelp powder has the effects of improving symptoms and completely eliminating disease roots, and is more difficult and expensive to act on hypertension, diabetes, hyperlipidemia, hyperuricemia, coronary heart disease, cerebrovascular disease and the like.
Potassium supplement and sodium discharge: natural potassium is known as a long life factor for reducing hypertension and cardiovascular and cerebrovascular diseases of old people, and high-potassium low-sodium diet can obviously reduce the risk of hypertension and apoplexy of patients. The incidence of cardiovascular and cerebrovascular diseases and hypertension of local people in the Russian Gaogansu area, which is one of the five famous longevity countries in the world, is far lower than that of other areas in the world, and the root cause of the disease is that the local people are interested in eating the food pickled by sylvite with very high potassium content through expert investigation, so that the incidence of the hypertension and the cardiovascular and cerebrovascular diseases is greatly reduced, and the local people have long lives due to the fact that the latest scientific research shows that: natural high-quality potassium can inhibit sodium absorption and expel sodium ions in blood out of the body, so that the blood pressure of a human body is obviously reduced, the stroke probability of hypertension is greatly reduced, the potassium can soften and protect blood vessels, the arterial wall can be prevented from thickening, the phenomena of blood coagulation and the like can be prevented, cerebral blood in the brain of the human body is regulated, the cardiac muscle function is activated, the self-regulation function of the human body on the blood pressure is effectively recovered and strengthened, and therefore, potassium supplement and sodium discharge are advocated by the medical community as the most scientific, safe and efficient blood pressure reduction mode at present.
Maintenance of blood vessels, in particular prevention of stroke: the disease of cerebral apoplexy is caused by cerebrovascular occlusion and cerebrovascular rupture, while the low-potassium kelp powder can permeate into cerebral capillaries to remove free radicals, sodium ions and thrombus residues attached to the vessel wall in the cerebral vessels. The thrombus and blood clots are removed, and the residues enter the blood circulation of the aorta and are discharged outside the body. The kelp powder with low potassium has the functions of softening blood vessel, making blood vessel elastic, and preventing hard lump and rupture. The low-potassium kelp powder inhibits the concentration rise of free calcium ions in vascular smooth muscle cytoplasm by cleaning cholesterol impurities attached to the vascular wall, thereby preventing the synthesis of vascular smooth muscle DNA and protein and the thickening of the vascular wall, softening the blood vessel, discharging residues and blood clots in the blood vessel out of the body along with circulation and keeping the blood vessel of a human body in a young state.
Purifying blood: a large number of clinical trials prove that the low-potassium kelp powder can effectively reduce blood fat and blood sugar. The blood fat reducing effect is achieved by adsorbing cholesterol and triglyceride in blood flow through the low molecular state potassium alginate and discharging the cholesterol and triglyceride out of the body, the blood sugar reducing effect is that the low potassium kelp powder can compete with sugar more easily to a binding site of a-glycosidase, and when the site is occupied by the low molecular state potassium alginate, the blood sugar of a human body is adjusted to a normal level. In addition, the low molecular state potassium alginate with negative charges can break red blood pellets in blood, thereby obviously reducing blood viscosity blood clots of patients and preventing the formation of thrombus, and the low potassium kelp powder fundamentally purifies the blood environment of human bodies in various aspects.
And (3) cycle improvement: the low potassium kelp powder can improve the deformability of erythrocyte, increase oxygen and nutrient components in blood, and improve microcirculation.
The method replaces western medicines: the low-potassium kelp powder can be clinically shown to have the effect of inhibiting ACE vasodilatation similar to natural angiotensin converting enzyme, can reduce the level of aldehyde ketone in blood plasma, increase renal blood flow and reduce sodium retention, so that the low-potassium kelp powder has a very obvious blood pressure reducing effect through clinical verification, and indexes can be quantized and compared with any existing hypertension medicine.
Loosening bowel to relieve constipation: the low-potassium kelp powder contains hydroxyl fiber compounds, has the functions of wrapping water in intestinal tracts of human bodies and relaxing bowel, and accordingly solves the problem that old hypertension patients have constipation or cardiovascular and cerebrovascular accidents caused by the constipation.
And the pH value of the low-potassium kelp powder belongs to alkalescent medicines, so that the body constitution of a patient is alkaline after the patient eats the kelp powder for a long time, and the immunity is improved.
Through human body tests, the blood pressure of a tester at the moment is 180/110, the tester drops to 110/70 after eating the low-potassium kelp powder for one month, because the tester is older and uncomfortable, the blood pressure of the tester cannot drop too low, the tester is called to stop taking the kelp powder, the blood pressure of the tester rebounds to 130/90 after the test is ended for one month, the tester feels comfortable and normal to the tester, the tester trusts the curative effect of reducing the blood pressure, the tester cuts fingers in a kitchen to cut vegetables and before taking the low-potassium kelp powder, the blood viscosity is sticky, the blood viscosity tends to be normal after taking the kelp powder, the hemagglutination phenomenon can be prevented, in addition, a researcher who talks about Liu mr who is in the middle school, the body can bear any burden to carry out scientific research to obtain the cardiovascular and cerebrovascular diseases, the heart bridges, and the friend prepares the medicines for three months later, after one month, the blood pressure of the patient is obviously reduced, the pace-beating of the heart is normal, the patient uses the prepared medicine to treat the mother, the mother is a 90-month old person, the hypertension of the family history of the mother is reduced after the patient eats the medicine for one month, the patient is very cherished, and the patient does a blood type check to find that the blood pressure and the potassium elements of the patient are normal and can not cause the hypertension, so that the low-potassium kelp powder is very safe to the human body and can not cause the hyperkalemia!
The inventor of Liu Gong assist in the study of the fact that low molecular state potassium alginate has obvious curative effect requirements and continues to take the medicine, seriously declares that the kidney function and the heart and lung of the patient before taking the medicine are normal and the patient does not have hyperkalemia.
The potassium [ K + ] test result is 4.7mmol/L, and the reference value is 3.50mmol/L-5.50 mmol/L.
The method for researching the influence of the low-potassium kelp powder on the blood pressure of Spontaneous Hypertensive Rats (SHRs) and the pharmacokinetic law in mice adopts a tail pulse indirect pressure measurement method to measure the systolic pressure of the SHRs, and 40 rats are randomly divided into 5 groups: a blank solvent control group, a hydrochlorothiazide tablet group (6.25mg/kg), a low molecular state potassium alginate high dose, medium dose and low dose group (500, 250 and 100mg/kg), and the administration is performed by intragastric administration every day for 28 days continuously; measuring blood pressure every week, observing blood pressure changes of 3d and 6d after drug withdrawal, irrigating KM mice with 100mg/kg (74MBq/kg) of low-potassium kelp powder for 3 days, taking blood from tail parts of 2, 5, 10, 20, 30min and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120 and 144h after drug administration, measuring sample radioactivity, fitting pharmacokinetic parameters of the low-potassium kelp powder orally administered in the mice by DAS2.0 software, and comparing the results with a solvent control group at the same period, the blood pressure levels of SHRs of 3 dose groups continuously administered with 21d and 28d, hydrochlorothiazide and low-potassium kelp powder are averagely reduced (P is less than 0.01); when stopping taking the medicines for 3d and 6d, the pressure reducing effect of 6.25mg/kg hydrochlorothiazide disappears (P is more than 0.05); when stopping for 3d, the systolic blood pressure of the high, medium and low 3 dosage groups of the low molecular state potassium alginate is averagely lower than that of the synchronous solvent control group (P <0.05 or P < 0.01); when the medicine is stopped for 6 days, 250 and 500mg/kg of low-potassium kelp powder can still reduce the blood pressure level (P is less than 0.01) of SHRs, the pharmacokinetics law of the low-potassium kelp powder in a mouse body after gastric lavage meets a biventricular model, the half-life period of an absorption phase is 2.76h, the half-life period of a distribution phase is 42.30h, the half-life period of an elimination phase is 42.31h, and the half-life period in the body is 36.28 h.
And (4) conclusion: continuous oral administration of low-potassium kelp powder can reduce SHRs blood pressure dose-dependently, and withdrawal of 6d still shows sustained blood pressure reducing effect, which may be related to slow in vivo elimination of low-potassium kelp powder after oral administration.
The preparation method of the low-potassium kelp powder comprises the following steps:
the method comprises the following steps: after the kelp is cleaned, cellulase with the amount of 0.5 percent of the dry kelp is added to promote the enzymolysis of partial cell walls of the kelp into glucose micromolecules so as to improve the extraction rate of alginic acid.
Step two: after kelp is subjected to enzymolysis, adding a Na2CO3 solution with the mass fraction of 3%, wherein the temperature is 50 ℃, and the digestion time is 3 hours; adding alkali solution to convert calcium alginate into soluble sodium alginate, adding hydrochloric acid, converting calcium alginate into alginic acid under the action of hydrochloric acid, adding edible potassium chloride into alginic acid at a ratio of potassium chloride to alginic acid of 0.1:300, and filtering to remove residue to obtain potassium alginate.
Step three: adding alginate lyase into potassium alginate for degradation to obtain filtrate, wherein the optimal enzymolysis reaction conditions are that the pH is 5.0, the temperature is 45 ℃, the reaction time is 18h, and the enzyme adding amount is 100U/g.
Step four: ultrafiltering the filtrate by membrane separation technology, adding anhydrous ethanol to precipitate flocculent potassium alginate, and drying to obtain micromolecular potassium alginate, i.e. low-potassium kelp powder.
Secondly, the iodine has strong sterilization and special functions of adsorption, oxidation, virus resistance, DNA interaction and the like. However, since iodine is easily sublimed, it is common to compound iodine with various substrates to improve its stability, and conventional iodine compounds such as iodophors, iodine tincture, iodine anid, and cydiodine tablets, etc. Wherein the iodine tincture: can be used for treating skin infection and disinfection. Iodine glycerin: can be used for treating oral ulcer, gingivitis, and pericoronitis. Cydiodine tablet for treating chronic pharyngolaryngitis, oral ulcer, chronic gingivitis and periodontitis.
Iodine is a strong oxidant, can halogenate proteins of pathogenic microorganisms such as viruses, bacteria, fungi and the like, destroys active groups of protoplasm proteins of the viruses, the bacteria, the fungi and the like, is combined with amino acid of the proteins to denature the proteins so as to lose activity, and has strong killing effect. Moreover, iodine has very strong penetrating power to virus, bacteria and the like, and has quick action. It is surprising that iodine is used to kill respiratory infectious viruses, including new corona viruses.
Iodine is iodine simple substance or molecule, and the iodine simple substance or molecule is dissolved in water to prepare low-concentration iodine solution.
The preparation method of the iodine simple substance comprises the following steps:
the method comprises the following steps: selecting dried herba Zosterae Marinae, washing, and treating in pressure cooker at 120 deg.C under 0.1MPa for 30 min. Then leaching the mixture in 10 times of iodine-free water for 12 hours, and keeping the temperature at about 50 ℃. Filtering to obtain a yellow brown filtrate.
Step two: the filtrate was passed through a hollow fiber ultrafilter having molecular weights of 80000, 30000, l0000, and 3000 in order to remove macromolecular proteins, polysaccharides, and the like. Then concentrated in vacuo using a rotary evaporator at 80 degrees, 0.1 MaP.
Step three: enabling the concentrated solution to pass through anion exchange resin and cation exchange resin, adjusting the pH of the concentrated solution to 3-4, enabling the concentrated solution to pass through the anion exchange resin, and collecting effluent liquid; adjusting the pH value of the effluent to 9-10, passing through a cation exchange column, and collecting the effluent (the effluent contains organic iodine).
Eluting with anion and cation exchange resin, and collecting eluate (containing inorganic iodine).
Step four: iodizing by adding 6M sulfuric acid dropwise into the eluate, adding 10% NaNO2 solution dropwise, and precipitating with brown black precipitate.
Step five: centrifugal separation and refining: standing the crude iodine solution for clarification, carefully sucking out the supernatant, transferring the residual solution and crude iodine into a centrifugal test tube for centrifugal separation, and sucking out the supernatant to obtain crude iodine. Adding the crude iodine into concentrated sulfuric acid for melting, cooling and crystallizing to obtain pure iodine simple substance.
The detection method comprises the following steps:
firstly, sample treatment
Sample 2g (accurate to 0.1mg) is weighed into 500g of iodine-free salt and stirred well. Subpackaging into 50g bags for inspection.
Second, submission
Detecting total iodine according to national standard GB 5009.267-2016; detecting potassium iodate according to the national standard GB5009.42-2016 (common salt detection method).
Detection of iodine simple substance and potassium iodide
Weighing 10.0g of the sample to be detected, adding 40mL of iodine-free water, capping a triangular flask, shaking the flask at 50 ℃ for 60min, and filtering to obtain a constant volume of 50mL for later use.
Taking 5mL of the sample, adding 4 drops of sulfuric acid (1+3), and judging the existence form of iodine in the solution:
1. the method for judging the existence of the iodine simple substance comprises the following steps: 1 drop of 0.5% starch solution was added directly without turning blue. Indicating that no iodine exists in the solution.
2. The method for judging the existence of the iodide ions comprises the following steps: adding 1 drop of 0.5% starch solution, and then adding 0.5mol/L FeCl dropwise3The solution did not turn blue all the time during the dropping process. Indicating that no potassium iodide was present in the solution.
Fourth, judging the samples to be checked
If potassium iodate is not present in quantitative detection, iodine simple substance (I) is not present in qualitative analysis detection2) And no potassium iodide exists, so that the quality of the sample to be detected can be judged to be qualified.
If potassium iodate is present in quantitative detection, elemental iodine (I) is present in qualitative analysis detection2) And in the presence of potassium iodide, any one of the three items, the sample to be tested is unqualified.
Fifthly, calculating the content of organic iodine
As in the above detection, no iodine element (I)2) Iodine ion (I-) and Iodate (IO)3-) So the organic iodine is indirectly measured by referring to the international common subtraction method:
organic iodine is total iodine-inorganic iodine.
Claims (10)
1. A preparation method for preventing and treating new coronavirus and application thereof are characterized in that low-potassium kelp powder is prepared, the low-potassium kelp powder is prepared into spray containing the low-potassium kelp powder to be used for nasal cavities and throats, the low-potassium kelp powder is prepared into normal saline to be used for human body injection, the low-potassium kelp powder is prepared into capsules or tablets to be taken by people, and iodine simple substance can be extracted from cydiodine tablets or seaweed plants to kill virus or bacteria.
2. The preparation method and the application of the kelp powder for preventing and treating the new coronavirus according to claim 1, wherein the preparation method of the low-potassium kelp powder comprises the following steps:
the method comprises the following steps: after the kelp is cleaned, cellulase with the amount of 0.5 percent of the dry kelp is added to promote the enzymolysis of partial cell walls of the kelp into glucose micromolecules so as to improve the extraction rate of alginic acid.
Step two: adding Na with the mass fraction of 3 percent after the kelp is subjected to enzymolysis2CO3The solution is digested at 50 ℃ for 3 h; then adding alkali liquor to convert calcium alginate into soluble sodium alginate, adding hydrochloric acid, converting the calcium alginate into alginic acid under the action of the hydrochloric acid, adding edible potassium chloride into the alginic acid, wherein the ratio of the potassium chloride to the alginic acid is 0.1:300, and filtering to remove residues to obtain the potassium alginate.
Step three: adding alginate lyase into the potassium alginate for degradation to obtain a filtrate, wherein the optimal enzymolysis reaction conditions are that the pH is 5.0, the temperature is 45 ℃, the reaction time is 18h, and the enzyme adding amount is 100U/g.
Step four: and ultrafiltering the filtrate by adopting a membrane separation nano technology, adding absolute ethyl alcohol to separate out flocculent potassium alginate, and drying to obtain micromolecule potassium alginate, namely the low-potassium kelp powder.
3. The preparation method and the application of the iodine element for preventing and treating the new coronavirus according to claim 1, wherein the preparation method of the iodine element comprises the following steps:
the method comprises the following steps: selecting dried seaweed plants, washing the seaweed plants, placing the washed seaweed plants in a high-pressure container, carrying out heating treatment, placing the seaweed plants in iodine-free water for leaching after the heating treatment, wherein the leaching time is 12 hours, and keeping the iodine-free water at a constant temperature.
Step two: and (3) carrying out primary filtration to obtain a tawny filtrate, sequentially passing through middle control fiber ultrafilters with different specifications to remove substances such as macromolecular protein, polysaccharide and the like, and then carrying out vacuum concentration by using a rotary evaporator at the working temperature of 80 ℃ under the standard atmospheric pressure to obtain a concentrated solution.
Step three: respectively passing the concentrated solution through anion exchange resin and cation exchange resin, adjusting the pH value of the concentrated solution passing through the anion exchange resin, and collecting effluent passing through the anion exchange resin; adjusting the pH value of the concentrated solution passing through the cation exchange resin, collecting effluent passing through the cation exchange resin, respectively eluting the anion exchange resin and the cation exchange resin, and collecting eluent.
Step four: and (4) iodolysis: firstly, dripping sulfuric acid into the eluent to acidify the eluent, and then dripping NaNO into the eluent2A solution in which a brownish black precipitate is present in the eluent.
Step five: centrifugal separation and refining: and C, standing and clarifying the solution obtained in the fourth step, sucking out the supernatant, transferring the residual solution and the brownish black precipitate into a centrifugal test tube for centrifugal separation, sucking out the supernatant in the centrifugal test tube after centrifugal separation to obtain crude iodine, adding the crude iodine into concentrated sulfuric acid for melting, and cooling and crystallizing to obtain the pure iodine simple substance.
4. The preparation method and application of claim 3, wherein the seaweed is one or more of kelp, laver and seaweed.
5. The method as claimed in claim 3, wherein the pressure vessel is an autoclave and the pressure is 0.1 MPa.
6. The preparation method and the application of claim 3, wherein the heating temperature of the heating treatment is 120 ℃, the heating time is 30 minutes, and the constant temperature is 49-51 ℃.
7. The preparation method and the application of claim 3, wherein the hollow fiber ultrafilter has a pass molecular weight of 80000, 30000, 10000, 3000 respectively.
8. The preparation method and the application of claim 3, wherein the pH value of the concentrated solution passing through the anion exchange resin is 3-4, and the pH value of the concentrated solution passing through the cation exchange resin is 9-10.
9. The preparation method and application of claim 3, wherein the amount of sulfuric acid added dropwise is 6 ml, and the amount of NaNO added dropwise is 6 ml2The concentration of the solution was 10%.
10. The method for preparing and using the powder for preventing and treating new coronavirus according to claims 1-10, wherein the low-potassium kelp powder can be used for preventing and treating hypertension, critical hypertension, myocardial infarction and cerebral infarction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111025789.2A CN113952366A (en) | 2021-09-07 | 2021-09-07 | Configuration method and application for preventing and treating new coronavirus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111025789.2A CN113952366A (en) | 2021-09-07 | 2021-09-07 | Configuration method and application for preventing and treating new coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113952366A true CN113952366A (en) | 2022-01-21 |
Family
ID=79460980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111025789.2A Pending CN113952366A (en) | 2021-09-07 | 2021-09-07 | Configuration method and application for preventing and treating new coronavirus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113952366A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1597703A (en) * | 2004-08-20 | 2005-03-23 | 赵波 | Low molecular potassium alginate and its application |
| CN107836686A (en) * | 2016-09-19 | 2018-03-27 | 江苏井神盐化股份有限公司 | A kind of seaweed iodine nutritious liquid and sea-tangle toppings combine production method |
| CN112791097A (en) * | 2020-11-27 | 2021-05-14 | 金玉东 | Application of iodine in preparing medicament for preventing and treating respiratory infectious diseases and method for preparing low-particle-size iodine-containing aerosol |
-
2021
- 2021-09-07 CN CN202111025789.2A patent/CN113952366A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1597703A (en) * | 2004-08-20 | 2005-03-23 | 赵波 | Low molecular potassium alginate and its application |
| CN107836686A (en) * | 2016-09-19 | 2018-03-27 | 江苏井神盐化股份有限公司 | A kind of seaweed iodine nutritious liquid and sea-tangle toppings combine production method |
| CN112791097A (en) * | 2020-11-27 | 2021-05-14 | 金玉东 | Application of iodine in preparing medicament for preventing and treating respiratory infectious diseases and method for preparing low-particle-size iodine-containing aerosol |
Non-Patent Citations (3)
| Title |
|---|
| 唐思齐: "碘生产研究进展概况", 《海洋湖沼通报》 * |
| 唐思齐: "碘生产研究进展概况", 《海洋湖沼通报》, 31 December 1981 (1981-12-31), pages 64 - 66 * |
| 国晶晶: "褐藻中降血压活性物质及其提取工艺研究进展", 《食品工业科技》, no. 19, 31 December 2018 (2018-12-31), pages 321 - 323 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102070727B (en) | Extraction method of sodium heparin | |
| CN101886097B (en) | Preparation process for high purity theaflavin and application thereof in preparing anti-influenza virus medicines | |
| CN112521524B (en) | Composition for synergistically reducing blood sugar by using lycium barbarum polysaccharide and acaudina molpadioides functional peptide | |
| CN102994350A (en) | Preparation method of tartary buckwheat wine with function of reducing blood fat | |
| JP2009520716A (en) | Phaseolas vulgaris extracts, their use, and compositions containing them | |
| CN100425251C (en) | Pharmaceutical composition for treating bone diseases and method for preparing the same | |
| CN113952366A (en) | Configuration method and application for preventing and treating new coronavirus | |
| CN111991543A (en) | Traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia and preparation method thereof | |
| CN113875782A (en) | Externally applied spray for killing new coronavirus | |
| CN104800298B (en) | It is a kind of to be used to treat Chinese medicinal granular formulation of gout and preparation method thereof | |
| HIPP et al. | Spontaneous myoglobinuria: report of a case with symptoms of myotonia | |
| CN107537028B (en) | Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof | |
| CN102973558A (en) | Use of matrine in anti- influenza virus drug preparation | |
| CN114747766A (en) | Health-care food composition capable of reducing uric acid and preparation method and application thereof | |
| CN106720889A (en) | A kind of betel nut shitosan chewing gum lozenge and preparation method and application | |
| TWI763916B (en) | Cyanobacterial extracts, processes for preparing the same and uses thereof | |
| CN102973657B (en) | Cough-relieving Qinbaohong mixture and preparation method thereof | |
| KR101721042B1 (en) | A method for preparing a extract of placenta for oral | |
| CN101152262B (en) | Anti-gout novel medical preparation | |
| WO2021128234A1 (en) | Radix ophiopogonis degradation extract and application thereof in preparation of drugs for prevention and treatment of cardiovascular diseases | |
| CN110694025A (en) | Eight-treasure intelligence-benefiting compound and preparation method and application thereof | |
| CN101129774A (en) | Traditional Chinese medicine preparation for treating inflammation of oral cavity and method of producing the same | |
| WO2004030680A1 (en) | Pharmaceutical composition comprising bando deep ocean water of the concentrate thereof for treatment and prevention of liver disease | |
| CN1830998A (en) | Total extractives of steroid saponin, prepn. method and application thereof | |
| CN1232275C (en) | Enteroclysis liquid medicine for treating renal failure and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220121 |
|
| RJ01 | Rejection of invention patent application after publication |